“Global Urology Devices market set to grow to $9.3bn by 2023” says new Visiongain report

21 May 2019
Pharma

Visiongain has launched a new pharma report Urology Devices Market Report: Urinary Incontinence, Benign Prostatic Hyperplasia, Kidney Stone, Prostate Cancer.

In 2018, the urology devices market is estimated at $6.9 billion. The market is expected to grow at a CAGR of 6.1% from 2018 to 2029. Products included in the urology devices market include catheters, slings, brachytherapy, radiation therapy devices, accessories and others. The urinary incontinence market dominated the market in 2018 and accounted for 33.8% of the urology devices market.

The lead analyst of the report commented "The market is driven by a number of factors such as aging population, technological advancements, and increasing awareness programs. Other factors contributing to the growth of the market are preference for minimally invasive procedures and rising incidence of obesity. The market has certain restraining factors such as high cost of devices and social stigma associated with the disease."

Leading companies featured in the report include C.R. Bard, Coloplast, Endo Pharmaceuticals, Boston Scientific Corporation, Healthtronics, Lumenis, Medtronic, Siemens Healthcare, Urologix and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Visiongain Publishes Biological Imaging Reagents Market Report 2021-2031

Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.

13 November 2020

Read

Visiongain Publishes Antihypertensive Drugs Market Report 2021-2031

Hypertensive is the most common disease around the world. However, number of people suffering from hypertensive has increased very significantly from last few years. Hypertensive can occur due to consumption of tobacco, too much salt (sodium) and little potassium in your diet, alcohol and to people being overweight or obese.

13 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever